Purpose: Radiolabeled methionine (Met) promises to be useful in the positron emission tomography (PET) imaging of hepatocellular carcinoma (HCC). However, its metabolic routes in HCC have not yet been fully understood. In this study, the metabolic pathway(s) of radiolabeled Met in HCC were investigated. Procedures: To simulate the rapid blood clearance of radiolabeled Met, pulse-chase experiments were conducted. L-[methyl- H]-Met, the major intracellular uptake was found mostly in the protein phase and, to a lesser degree, in the phosphatidylethanolamine (PE) methylation pathway, which is fairly stabilized within the 55-min chase period (the main metabolites were SAM, Met, Met sulfoxide, and Met sulfone). In contrast, the uptake of Met in rat hepatocytes mainly points to phosphatidylcholine (PC) synthesis through the PE methylation pathway (the main metabolite was PC). Conclusions: This study demonstrated that different metabolic pathways of radiolabeled Met exist between HCC and surrounding hepatic tissue and contribute to the patterns of increased uptake of radiolabeled Met in HCC.
Introduction

I n our previous study (unpublished data), L-[methyl-
14 C]-methionine (Met) and L-[1- 14 C]-Met demonstrated different uptake patterns in the liver of a woodchuck model of hepatocellular carcinoma (HCC). Regions of HCC showed higher uptake of both radiolabeled Met compared to surrounding hepatic tissues. However, L-[methyl- 14 C]-Met also contributed to a substantial background uptake in the surrounding hepatic tissues, which compromised its contrast resolution. Conversely, L-[1-
14 C]-Met showed minimal background uptake and a higher tumor to liver (T/L) uptake ratio, suggesting that it may have a better potential for imaging HCC. Different uptake patterns imply different metabolic fates for these radiolabeled Mets in HCC. The study that explores the exact uptake metabolism(s) of L-[methyl-14C]-Met and L-[1-14C]-Met in HCC is urgently needed to facilitate the interpretation of positron emission tomography (PET) images of HCC using both tracers.
L-[methyl-
11 C]-Met has been shown to be useful for PET studies in a variety of malignant tumors [1] [2] [3] [4] [5] [6] [7] . Enhanced demand for Met in tumor cells is caused by increased fluxes in various Met metabolic pathways [8] . The major metabolic pathway of Met is shown in Fig. 1 . After transport into cells, Met can either be incorporated into protein synthesis or be converted into S-adenosylmethionine (SAM) via catalysis by the key enzyme Met adenosyltransferase. In the phosphatidylethanolamine (PE) methylation pathway, SAM reacts with PE to form S-adenosylhomocysteine (SAH), phosphatidylmonomethylethanolamine (PMME), and phosphatidyldimethylethanolamine (PDME) via catalysis by the key enzyme PE N-methyltransferase (PEMT); SAH can be decomposed back into Met, while PMME and PDME can immediately convert to phosphatidylcholine (PC). In normal brain and brain tumor tissue, the metabolic fate of L-[methyl- 11 C]-Met seems to be relatively simple, as it is assumed that contribution to the PE methylation pathway will be negligible and most of the Met will be incorporated into protein synthesis [9] .
The quality of PET imaging of HCC using L-[1-
C]-Met or L-[methyl-
11 C]-Met will depend on the metabolic fate of 11 C. In normal liver cells, the two radiolabeled function groups in Met follow different metabolic pathways (Supplemental Fig. 1 ). L-[methyl- 11 C]Met is thought to reflect PC synthesis via the PE methylation pathway [10] , while L-[1- 11 C]Met mainly tracks incorporation into protein synthesis [11] . In the case of HCC, the situation is more complex and the metabolic fates of radiolabeled Met are far from being well identified. Therefore, it is of critical importance to identify the exact mechanism(s) of radiolabeled Met metabolism in primary liver cancer, to better understand how the uptake of Met impacts the interpretation of the PET imaging data.
In the present study, the metabolism of radiolabeled Met was characterized in a woodchuck HCC cell line, WCH17 [12] , and in freshly derived rat hepatocytes. Due to the very short physical half-life of 11 C (20 min), 14 C-labeled 1-Met and 3 H-labeled methyl-Met were used for this study. Radiolabeled Met-derived metabolites were analyzed by radio thin layer chromatography (TLC). Detailed analysis of radiotracer metabolites enabled the elucidation of the mechanism underlying the higher uptake of L-[methyl- 
Materials and Methods
Materials
Cell Cultures
WCH17 cells in the exponential phase were trypsinized and were plated (1×10 7 cells/75 cm 2 flask) in 10 ml DMEM (contains 28.5 μM CHOL choride, 4,500 mg/l D-glucose, L-glutamine, and 110 mg/l sodium pyruvate; GIBCO/Invitrogen, Grand Island, NY, USA) supplemented with 10 % FBS and 1 % penicillinstreptomycin solution (10,000 U/ml penicillin and 10 μg/ml streptomycin) under a 10 % CO 2 -humidified atmosphere at 37°C. Freshly derived rat hepatocytes were purchased from Lonza Walkersville, Inc. (Walkersville, MD, USA) and maintained as the vendor's instruction. All experiments were carried out in triplicate, 24 h after plating. Fig. 1 . Metabolism of Met. Met methionine, SAM S-adenosylmethionine, SAH S-adenosylhomocysteine, PMME phosphatidylmonomethylethanolamine, PDME phosphatidyldimethylethanolamine, PE phosphatidylethanolamine, PC phosphatidylcholine, MAT methionine adenosyltransferase, PEMT phosphatidylethanolamine N-methyltransferase, LATLamino acid transporter.
Pulse-Chase Study
In order to mimic in vivo conditions, pulse-chase experiments were used to investigate the transient change of intracellular metabolites derived from radiolabeled Met. Cells were preincubated with a protein synthesis inhibitor 500 μg/ml cycloheximide (treated) or without cycloheximide (untreated) for 2 h [10, [13] [14] [15] . Cells were then incubated in 10 ml of HBSS containing 370 KBq of either
14 C]-Met (American Radiolabeled Chemicals, Inc., St. Louis, MO, USA) for 5 min at 37°C (pulse). After incubation, the media were removed and the cells were washed three times with PBS. The cells were then incubated in 10 ml of HBSS containing nonradioactive L-Met at the same concentration as radiolabeled Met for 10, 25, 40, and 55 min (chase); the treated condition had 500 μg/ml cycloheximide supplemented into the chase media, while the untreated group did not. After the chase, the cells were rinsed twice with PBS, trypsinized with 3 ml trypsin, and neutralized with 3 ml of ice-cold DMEM. Cell suspensions were centrifuged at 1,500×g at 4°C for 10 min and the supernatants subsequently discarded. Cell pellets were resuspended in 1.2 ml icecold 0.4 M perchloric acid (HClO 4 ) containing 100 mg/l BHT and incubated on ice for 30 min. The cell pellets were homogenized on ice for 3 min and the homogenate used for the extraction of radiolabeled metabolites.
Extraction of Radiolabeled Metabolites
From each 1.2 ml sample of homogenate, 0.1 ml was used to measure the total radioactivity with liquid scintillation counting using a Beckman LS-6500 Liquid Scintillation Counter (Beckman Coulter Inc., Fullerton, CA, USA) and Bio-Safe II (Fisher Scientific Inc., Pittsburgh, PA, USA) as the scintillation fluid. Disintegrations per minute were obtained by correcting for background activity and counter efficiency based on counts of calibrated standards. Another 0.1 ml of homogenate was used for protein quantification using the Bradford method (Bio-Rad Laboratories, Inc., Hercules, CA, USA) [16] .
The remaining 1 ml homogenate was used for the extraction of radiolabeled metabolites following a previously described procedure [17] with modification (Supplemental Fig. 2) . Briefly, 1 ml homogenate was centrifuged at 3,000×g for 5 min and separated into acid-precipitable fraction (APF) and acid-soluble fraction (ASF) (step 1). The major radioactive components in the APF include lipids (PMME, PDME, and PC), RNA, DNA, protein, etc. The major radioactive metabolites of the ASF include Met, SAM, SAH, etc. The APF and ASF were further extracted in 2:1 chloroform/methanol and centrifuged at 3,000×g for 10 min to divide the whole mixture into water-soluble and lipid-soluble fractions (step 2). The water-soluble fraction was further separated into individual radioactive metabolites (Met, SAM, and SAH) as described in the next paragraph.
The precipitate from APF at step 2 was dissolved in 1 ml 0.3 M KOH and incubated at 37°C for 1 h, after which 0.32 ml 3 N perchloric acid was added. The mixture sat on ice for 5 min. At this step, the supernatant at this step is an alkaline-labile fraction containing RNA hydrolysate (step 3). The precipitate from step 3 was resuspended in 1 ml of 0.5 M perchloric acid and heated at 90°C for 15 min. The supernatant at this step is an acid-labile fraction containing DNA hydrolysate (since there is no pathway to derive DNA from Met, this might be derived from basic protein, such as chromosomal histone) (step 4). The final precipitate is protein.
Analysis of Radioactive Metabolites in Water-Soluble Fraction
The water-soluble radioactive metabolites were analyzed by Ricerca Biosciences, LLC (Cleveland, OH, USA) with a contract service. Briefly, silica gel G plate with concentration zone (Merck KGaA, Gibbstown, NJ, USA) was used for TLC analysis. Samples or standards were spotted into pre-adsorbent zones of individually labeled lanes and allowed to air-dry. Eluant was made fresh and allowed to pre-equilibrate in the TLC tank for ∼10 min prior to elution. The mobile phase consisted of butanol/acetic acid/water (2:1:2, v/v/v). The water-soluble metabolites were separated and identified via comparison of the retention factor (R f ) with those of the cold standards. The R f is defined as the ratio of moving distance of the compound to the moving distance of the solvent from the origin [18] . The plate was eluted to a distance of 15 cm with an elapsed time of ∼3 h. The plate was then air-dried and visualized using short wave UV light (handheld lamp), and sample lanes were scanned using the Bioscan AR 2000 (Bioscan Inc., Washington, DC, USA) to quantify the incorporation of radioactivity in each metabolite. The 
Statistical Analysis
The results are reported as the average±standard deviation. The data were compared using one-way analysis of variance (ANOVA) or ANOVA on ranks, when appropriate. All pairwise multiple comparison procedures used Tukey's honestly significant difference test. Differences were regarded as statistically significant for p valuesG0.05.
Results
Radiolabeled Met has a rapid circulation and clearance during PET imaging. In order to mimic this in vivo condition, pulse-chase experiments were used to investigate the transient change of the intracellular metabolites derived from
Radiolabeled Met Metabolism
For L-[methyl-3 H]-Met, rat hepatocytes and WCH17 cells were pulsed for 5 min and then chased for various durations (Fig. 2) . For both cell types, the total radioactivity content within the collected cells increased with the duration of the chase; however, the total radioactivity retained into WCH17 cells was around tenfold higher than that in rat hepatocytes during the whole pulse and chase period (pG0.001) (Fig. 2) .
In WCH17 cells, the levels of 3 H in the water-soluble phase were the highest at the early pulse period, and then the levels of 3 H in the protein phase derived from the APF started to increase and exceed the levels of 3 H in the water-soluble phase at the late pulse and whole chase periods (Fig. 2a) . A certain amount of 3 H in the RNA and DNA phases also accumulated throughout the pulse-chase period. Interestingly, very low levels of 3 H were observed in the lipid-soluble phase during the pulse-chase period. On the other hand, in rat hepatocytes, the levels of 3 H in the lipid-soluble phase were significantly higher than other phases during the whole pulse-chase period (Fig. 2b) .
For both cell types, the uptake patterns of L-[1-
(1) In rat hepatocytes, the uptake of L-[1-
14 C]-Met was twofold less than that of L-[methyl-
3 H]-Met; (2) in WCH17 cells, the level of 14 C derived from the APF in the protein phase was much higher than that in the water-soluble phase during the pulse-chase period; (3) in rat hepatocytes, the greatest accumulation of 14 C was found in the protein phase, as opposed to the lipid-soluble phase; and (4) in both cell types, the lipid-soluble phase had negligible levels of radiolabeled metabolites.
Effect of Cycloheximide on Tracer Uptake, Metabolism, and Protein Incorporation
The effects of inhibiting protein synthesis with cycloheximide on liver metabolism were also investigated. Fig. 4 illustrates the effect of cycloheximide treatment on the uptake of L-[methyl-
3 H]-Met in WCH17 cells and rat hepatocytes. In WCH17 cells, total radioactivity increased with the duration of the chase period. Total radioactivity retained in WCH17 cells during the whole pulse and chase period was significantly higher than that in rat hepatocytes (pG0.001). The largest accumulation of 3 H in WCH17 cells was in the water-soluble fraction, while the radioactivity in the protein, DNA, and RNA phases were negligible (Fig. 4a) . In contrast, the radioactivity in rat hepatocytes increased for the first 10 min and decreased gradually (Fig. 4b) . The largest accumulation of 3 H in rat hepatocytes was in the lipid-soluble phase. Fig. 5 shows the effect of treatment with cycloheximide on the uptake of L-[1-
14 C]-Met in WCH17 cells and rat hepatocytes. As compared to the uptake pattern with untreated cells, total radioactivity in both cells decreased with the duration of the chase (Fig. 3vs. Fig. 5 ). In both cell types, the distribution of radioactivity was similar: (1) the greatest levels of radioactivity were found in the watersoluble phase; (2) the radioactivity contained in the lipidsoluble phase was negligible; and (3) due to the effect of cycloheximide inhibition, radioactivity in the protein phase of treated cells was very low. 
Radiolabeled Metabolites Extracted from the Water-Soluble Phase
major L-[methyl-
3 H]-Met metabolites in the water-soluble phase were 3 H-SAM, 3 H-Met sulfone, 3 H-Met sulfoxide, and 3 H-Met. However, in rat hepatocytes, the major 3 Hlabeled metabolites in the water-soluble phase were undetectable due to their rapid conversion to lipids (PC, PMME, and PDME) that is generally observed in hepatocytes.
In WCH17 cells, the major L-[1-
14 C]-Met metabolites in the water-soluble phase were 14 C-SAM, 
Discussion
This study demonstrated the existence of different metabolic fates for radiolabeled Met in WCH17 cells and rat hepatocytes in addition to distinct uptake mechanisms for Fig. 1a) . PEMT has two isoforms. An isoform, PEMT2, has been found in a mitochondria-associated membrane in rat liver. Interestingly, PEMT2 might have an exclusive role in the regulation of hepatoma cell division, and its expression in rat hepatoma cells can specifically suppress cell division [20] . In this study, the PE methylation pathway in HCC was disrupted, and conversion of L-[methyl-3 H]-Met-derived SAM into lipid (PC, PMME, and PDME) occurred slowly even when protein synthesis was inhibited. These data suggest that PEMT activity may be much lower in WCH17 cells compared to primary hepatocytes, implying a state of high cell division and DNA replication occurring in HCC cells. Low PEMT activity in HCC cells could divert the metabolic pathway of L-[methyl-
3 H]-Met towards protein synthesis and, to a lesser degree, cause the intermediate metabolites to accumulate in the water-soluble phase. Similarly, conversion of metabolites from the water-soluble phase to the lipidsoluble phase may be impaired.
In contrast, PEMT activity was high in rat hepatocytes and the route from water-soluble phase to lipid-soluble phase was clear. Thus, the predominant pathway for metabolites derived from L-[methyl-
3 H]-Met in hepatocytes was lipid synthesis. It is still unknown why lipid synthesis overwhelms protein synthesis during the metabolism of L-[methyl-
3 H]-Met in primary hepatocytes. One possible explanation is physiological adaption of primary hepatocytes. Lipids (PC, PMME, and PDME) derived from the cytidine diphosphate (CDP)-choline and PE methylation pathways possess inverse physiological functions. PC derived from the PE methylation pathway will suppress cell division and DNA replication, while PC derived from the CDP-choline pathway will accelerate the rate of cell division of hepatoma cells grown in culture and of hepatocytes in intact animals [20, 21] . As such, a high level of PEMT2 expression and the preference for lipid synthesis over protein synthesis in primary hepatocytes may represent a physiological adaption, i.e., a mechanism possessed by normal hepatocytes that controls the rate of cell division. Within the same metabolic context, it stands to reason that there is a lack of PEMT activity in HCC.
Superior Contrast Uptake of L-[1-
-Met Despite Common Incorporation into Protein Synthesis
Normal liver tissue synthesizes many Met-derived secretory proteins, notably albumin, immunoglobulin G (IgG), highmolecular-weight materials, and low-molecular-weight materials [10] . In normal liver, within 1 h postinjection, 80 % of the radioactivity released into the plasma from L-[methyl-3 H]-Met metabolism was detected in the albumin fraction, while radioactivity in the IgG and high-molecular-weight fractions was minor [10] . Albumin biosynthesis and secretion are characteristic functions of normal rat liver, with albumin being the most prominent protein synthesized by the adult organ. Serum albumin is responsible for maintaining the osmotic equilibrium of body fluids and plays an important role in the transport of various essential metabolites and cellular constituents [22, 23] .
During hepatic neoplasm, genetic regulation of albumin synthesis may be altered. Studies have shown that hepatoma cells lose their capacity to synthesize albumins, which causes up to a fourfold decrease in albumin release compared to primary hepatocytes [22, 23] 
Implication for In Vivo PET Imaging of HCC with Radiolabeled Met
The present study investigating the metabolism and uptake of radiolabeled Met in HCC provides insights to aid the quantitative analysis of PET imaging of HCC with radiolabeled Met and the interpretation of image results, e.g., studies on tracer kinetics via compartment modeling analysis. In our previous imaging study, WCH17 cells displayed a faster and greater accumulation of radiolabeled Met compared to surrounding hepatic tissues. This implies that, to model the rate of Met transport, investigators should anticipate a greater rate of transport in regions of HCC compared to the surrounding hepatic tissues during parameter estimation.
Radiolabeled Met transported into HCC cells was rapidly incorporated into protein or converted into SAM. Thus, the parameter for the influx rate between the free Met compartment and the metabolized Met compartment in HCC cells should represent a combination of protein synthesis rate and Met transmethylation rate; due to the suppression of secretory protein synthesis in HCC, the parameter for the rate of outflux from the metabolized Met compartment in HCC cells can be ignored. In contrast, the patterns observed in primary hepatocytes point to the PE methylation pathway. As such, the parameter for the influx rate between the free Met compartment and the metabolized Met compartment in primary hepatocytes should predominantly represent the Met transmethylation rate. In the context of PET imaging using L-[1-
11 C]-Met, although both WCH17 cells and primary hepatocytes incorporate radiolabeled Met in protein synthesis, a significantly higher rate of protein synthesis is expected in WCH17 cells as compared to surrounding hepatic tissues.
Taken together, this metabolism study will be useful for the development and validation of a compartment model for kinetic analysis of Met radiotracers. Such a model would enable the estimation of the higher rate of Met transport into HCC and the higher rate of protein synthesis and/or Met transmethylation based on different labeling positions compared to surrounding hepatic tissues. The resulting parameters could be quantitatively useful, for example, for the early detection of HCC and/or monitoring the treatment response in HCC patients.
This in vitro metabolism study obtained basic information on the metabolism of radiolabeled Met in HCC cells without confounding influences, such as microenvironments, nonneoplastic cells, precancerous cells, competing plasma substrates, and heterogeneity of cancers. Validation of the applicability of these in vitro observations to in vivo conditions requires in vivo evaluation of the patterns of Met metabolism in both experimental and human HCC tumors.
Conclusion
This study demonstrated that distinct metabolic fates exist for radiolabeled Met in HCC cells and hepatocytes. In the context of our previous study, these patterns are likely to be responsible for the enhanced uptake of Met in PET imaging of HCC. In HCC cells, the major metabolic fate of L-[methyl-
3 H]-Met was protein synthesis and, to a lesser degree, the PE methylation pathway. However, in primary hepatocytes, lipid synthesis was the predominant metabolic fate of L-[methyl-
3 H]-Met; these 3 H-radiolabeled lipids (PC, PMME, and PDME) that were produced contribute to the background contrast observed in PET imaging of HCC using 
